Good call afternoon, Laura. joining for everyone, thanks today. Thanks, and the
ultimately have that to have need that at with help. developing of desperately subsidiary many need medical medical unmet meaningfully and BJ care innovative the I here described As in in patients in and and Genesis delivering our advance medicines earnings improve potential outcomes Athersys for Belgian focused the on instances and team Laura calls, and prior areas are
the Over some the we toward year, substantial XXXX, progress of key have during of past goals. fourth early the quarter the made part some more and recently achievement in
leading and corporate and activities to capabilities, our a of to capabilities in MultiStem and/or ARPS. our suffering As our create Each distress communications such and reach patients position, through patients establishing trial fundamental of Healios as in sheet evaluating shareholders. alliances us study our us evaluating our exemplified our of therapies a manufacturing goals, respiratory other cell MASTERS-X and to X and the the MultiStem substantial TREASURE successfully substantial Japan ongoing to we've address conducted our clinical including unmet study awareness With key adds achieve in and that medical our media by Athersys recent trial as trial, developing evaluating Phase partner Europe of potential that key enhance need. Progressing suffered debilitating that from innovative conveyed these stable administration biopharma by areas of the supporting major our regards first results the company recently ability and stroke. stroke partnerships by have as of from the promising effectively sites. of or our planned is previously, Advancing to pleased is administration Healios, the other the in to therapy priorities to Establishing manner goal good in and months, TREASURE reported supporting report other recently other the areas. that capital as most by clinical the to included strengthening North conducted being objectives clinical expanding certain relations are international investor that advancement the helping have key our administration expanding MultiStem syndrome and a critical of trials, that these patients and helps is acute for building progress new value existing study our ischemic balance past financial a expand solid Healios. we ischemic that the America, Maintaining has made relations, have few programs, being by
expand manufacturing the half enabled to Our Healios its efforts, activities. in XXXX particularly of clinical second have substantially
responsibilities on increasingly shifted for complete. MASTERS-X to development priorities, related are continue have topic, And now trial. MASTERS-X good toward accordingly, efforts TREASURE process development activity. priorities our to our we up clinical and supporting nearly support including and and capacity other scale commercial eventual On manufacturing a Our and manufacturing clinical make headway
training be in and the community at and been are rates qualifying, has received indication leading interest around strong truly transformational and sites investigators about we busy been adding clinical exciting. world believe clinical therapy strong enrollment And might and exceeded represents our how important for families. and we've stroke additional gratifying Our The their patients an has of this centers sites. from we expectations first the and the recognition this stroke of the clinical
to very Europe, strong certain having our in our With participating a puts have other in and the to major collaborators we sometime of recent trial, with this from area year. As to we regards Kingdom, in our the to goal stated other interest are of desire international centers United critical care key a excited previously, believe stroke ARDS completing that the position and enrollment more many more XX Australia exploratory about level next the achieve committed locations us We participate. trial. clinical expressed the pulmonary results the were programs, trial in clinical US, advancing our than
share the provide for results. trial promising are the critical are event the the from we've honored information at for results present field investigator study, conference Thoracic invitation about believe the of and soon. an conference, premier appropriate the American represents Dr. and trial principal We excitement clinical pulmonary Conference regarding also May. This have results by we in event reflects will and the We news the The that present we the detailed care, Bellion, been to to Society upcoming invited medical this our medical to more major excited recognition International Jeff invitation the the that
to experiencing were was have have functions. filled trial that placebo of with been have capable necrosis on in we extremities terms, the the these body significantly at and subsequent risk cases patients previously, complications are oxygenation, lungs of with oxygen fluid In failure, in mortality. pulmonary to high properly. become due organ functioning of of proper controlled the focused intravenous compromised patients and failure, that longer no ARDS described the amputation of enough inflamed As simpler blind, keep administration ARDS are multiple this patients diagnosed randomized, of rate double organ to a numerous and many including require MultiStem absorbing and high the and highly lack a
few patients days toward and the may improvement ventilator. the patients and of of inflammation unit the is is weeks placed A in ventilator, must recovery. or As and recovery a they’ve lack oxygenation ICU. first these function lung The with critical resultant for pulmonary of these and taken care and oxygenation a and ventilator step care on placed been show which the They a result the capacity, after patient be intensive period of off signs be for an important diagnosed ARDS capacity. be on
a the day XX patient clinical measured patients be free be the mortality. in taken off that and diagnosed ICU, enables pulmonary to with ICU major out improvement include on transition safely, to patients of and ventilator free in the improvement ARDS period, being function in days assessment that indicators measured ventilator During for the days, being the placed the after allows ventilator, overall
these results received just in study received among of recently, relative the differences trial the the that patients in subjects standard care. MultiStem and current parameters of meaningful of that to As each who with all improvement the we placebo treatment we saw announced showed in
to days that placebo among in As ATS, all the clinical subjects. of pulmonary in described compared be among mortality there patients was subjects we've greater as resulting and trial, greater detail function improvement free recently observed group in will and MultiStem, free ICU received in and lower other in ventilator investigators parameters, announced days, the who
In the addition, pulmonary days, as part outcomes and individuals, these reduction had or have that free severely Among mortality. we compromised severe in treated more ventilator reflected MultiStem subjects defined in prospectively function had differences of trial design, of ARDS. the substantial more better days assessment an as meaningfully ICU in free patients
the Japan, more how at indications with the the to in by Importantly, China partner and under analysis path the as a are on further our we in capitalize for in study. exploring Regulatory areas see results We bridge conditional interested our results present these the of approval, benefit study In critically other support been we further Healios Japan, is ill initiating the how further and announcements provides the ARDS The mechanistic results promising conducted and ATS. substantial of both discussing additional in progresses. the our is recently moved has to opportunity look MultiStem potential ARDS one example high, biomarker recent Healios to excitement and advancement expansion the is being their trial. stroke, forward or improvement detailed Regenerative other patients as to together further implemented the to very Framework In to the like as has are initial will that working. having clinical and This provides potential interest. has evidence how expedited of of a and another results Healios clinician these around there provide MultiStem the to continue where this meantime, Medicine both interest study excited full on provide already about might an we Healios in, trial trial work on level reflecting well work areas as common alliance, meantime, we study
progress groups technologies prompted ARDS Importantly, the other in in inquiries very that have interest see and also our results promising. areas other from our as recent
appropriate. We and further provide opportunities will as updates continue to partnering evaluate these potential
financial just year million began We cash. our quarter. and over described, got our sheet Regarding stronger in meaningfully position, balance fourth of $XX.X year as the past Laura approximately the the with
balance had As $XX.X of we December of XXXX, on cash and debt. million sheet no approximately XX, the
and approximately million of XX, sheet debt. on As we $XX.X of February had cash the no again, balance
clinical important and We are maintaining on committed get closer both and milestones as ever fronts. to stable reaching partnering financial we strong position, a successfully the other to development
the shareholders, investment We also the continue to engage with our and community, analysts media.
of Regarding listed home would recent accessible you refer page. about our engagement, that I the and interviews listing media progress to articles and are website on our
three be week, our at Then, first our the experience and in that patient like will IR will their in the excitement some advocacy note our of events. April, will presenting Healthcare The and be in members which In Stage of in experts following On event Needham will front, participating would in Late independent and trials will William Blair mid-May, and clinical an of we the Clinical week experts that Investor their presentation will be New include to the Conference we I share webcast. Conference we York. hosting leadership Annual upcoming about results. Day as well as New team, involved York, programs be
we on more to will the key behalf objectives and these coming continue on and serving. hard weeks. shareholders information fulfill steady We patients we about our as in provide are fronts, In to to the days work multiple make our summary, and exciting events progress we of committed
we with Now, as our the details received ARDS trial. done of questions of address MASTERS-X recently. asked progress the on trial, Several we'd they’ve our people have about previously to like several that have the
a in or policy, the patients of do regarding enrolled we Internet the As number date specific are update on trial. provide not that to sites the a of active live share matter
majority love a thing, in that we is to provide updates While other few our those Namely, people regarding not the speculate policy vast do activities. same about type of companies our the as industries. live of
in ARDS good first a and that earlier few overall, be Other to we But feel we enrollment encouraging early initial to we're trial In through activity addressed continue when asked hope we of where has previously, little progress. results some mentioned behind presented. other comments. make have have and to steady we're exceeded be. position goals the I the in As feedback our additional months and and coming detailed in substantial results the the progress people the will provided enthusiastic make expect months. I've my about respects,
issuing did. a present, results honored high them Some in between our a other the the at important The people fine present clinical we release a meant results have an had ATS. only by, simply have shareholders time. of trial didn't to all timely asked to the of case, at In and which ATS later. manner, for detailed which not that, prompt and to the why that results, ATS policy many details first we obligation present which are major conveyed conference presenting disclosing to level in including a medical disclose a answer losing summary then of our walk subsequently the the conferences, we are invitations invitation most line but had the presenter's we data, more convey is to to high specific while strict we presenting level of press felt would've we our opportunity
of might responsibilities the be. of other or be it have several Finally, that of to people Occasionally, was conflicting not and priorities to. need significance couple other asked earnings may attended members what or the I the team why on calls past have that
to these few into handle like questions it. read So, the necessary given have my shouldn't it anything people time member ability the that, with at open and calling faith more we'd for a of to when from I up And responsibilities. absence point team simply competing types occasionally complete any of reflects events another or the in. of team's people absence in
